A core focus of our pipeline is to be able to address early stage primary cancers or locally accessible cancers via intra-lesional administrations – we believe there will be an increasing opportunity to identify cancers early. This will create a need for better early stage treatment strategies that are both highly curative for the primary disease but can also provide systemic protection that prevents further disease dissemination.
SP-002 — Basal Cell Nevus Syndrome
SP-002 is a combination therapy based on an adenovirus 5 vector encoding Interferon-gamma used in conjunction with a small molecule pathway inhibitor that targets both basal cell carcinomas and stromal cells within the tumor micro environment that create an immune-privileged site. The combination therapy allows lower doses of both agents to be used and to reverse immunosuppressive Basal Cell Carcinoma microenvironment. The small molecule pathway inhibitor also attenuates the normal negative feedback that suppresses signalling through Interferon-gamma receptor pathway. The combination therapy has been developed to allow multiple basal cell carcinomas to be treated concurrently with curative outcomes in nevus patients. The combination therapy is also designed to enhance abscopal responses against BCCs that have not been injected with the agents in nevus patients.
SP-102 – Sporadic Basal Cell Carcinoma
SP-102 comprises the same combination as SP-002 – an adenovirus 5 vector encoding Interferon-gamma and a small molecule pathway inhibitor. However, with SP-102, the small molecule inhibitor is formulated as a controlled release intralesional injection. This product has been developed to achieve superior tolerability but also with a high cure rate that is important for the treatment of subjects with a single nodular or superficial BCC lesion.
SP-003 – Sporadic Basal Cell Carcinoma and Cutaneous Squamous Cell Carcinomas
SP-003 is a combination therapy based on an adenovirus 5 vector encoding Interferon-gamma used in conjunction with a small molecule inhibitor reverses a potent immune-suppressive pathway that is induced by Interferon-gamma signalling and are common in both sporadic Basal Cell Carcinomas and Squamous Cell Carcinomas. The combination therapy has been designed to be extremely safe, well tolerated and is designed to treat single nodular and superficial sporadic basal cell carcinomas with curative intent and good cosmesis.
SP-006 – Advance cancers
SP-006 is a combination therapy based on an adenovirus 5 vector encoding Interferon-gamma used in conjunction with a second adenovirus encoding a biological that can stimulate an important cell surface receptor expressed on key stromal cell types (including Cancer Associated Fibroblasts) within the tumor microenvironment. The combination therapy is expected to enable remodeling of the highly fibrotic and rigid tumor stroma found in advance (desmoplastic type) cancers thereby rendering the tumors more susceptible to immune mediated treatments.
